Recurrence of hepatocellular carcinoma after resection or ablation with curative intent is common and not prevented by direct-acting antiviral agent (DAA) therapy for hepatitis C. Owing to multiple methodological inconsistencies, available studies fail to answer whether DAA therapy anticipated risk of severe tumour recurrence: a prospective randomized study might serve the purpose.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
High density Huh7.5 cell hollow fiber bioreactor culture for high-yield production of hepatitis C virus and studies of antivirals
Scientific Reports Open Access 30 November 2018
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Backus, L. I. et al. Impact of sustained virologic response with direct-acting antiviral treatment on mortality in patients with advanced liver disease. Hepatology https://doi.org/10.1002/hep.29408 (2017).
Backus, L. I. et al. Direct-acting antiviral sustained virologic response: impact on mortality in patients without advanced liver disease. Hepatology https://doi.org/10.1002/hep.29811 (2018).
Huang, A. C. et al. Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout. Hepatology https://doi.org/10.1002/hep.29855 (2018).
Roche, B. et al. The impact of treatment of hepatitis C with DAAs on the occurrence of HCC. Liver Int. 38 (Suppl. 1), 139–145.
Terrault, N. A. et al. International liver transplantation society consensus statement on hepatitis c management in liver transplant candidates. Transplantation 101, 945–955 (2017).
Reig, M. et al. Liver cancer emergence associated with antiviral treatment: an immune surveillance failure? Semin. Liver Dis. 37, 109–118 (2017).
Reig, M. et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J. Hepatol. 65, 719–726 (2016).
Colombo, M. & Boccaccio, V. Hepatitis C eradication with DAA and risk of liver cancer recurrence: the debate unrests. J. Viral. Hepat. https://doi.org/10.1111/jvh.12862 (2018).
Singal, A. G. et al. Direct acting antiviral therapy is associated with shorter time to HCC recurrence but not increased risk of recurrence [abstract]. Hepatology 66 (Suppl. 1), 729A (2017).
Cabibbo, G. et al. Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. J. Hepatol. 67, 65–71 (2017).
M.C. has served on the advisory committees for AbbVie, Achillion, AlfaWasserman, Bayer, Bristol–Myers Squibb, GenSpera, Gilead Science, GlaxoSmithKline, Janssen, Jennerex, Lundbeck, MSD, Novartis, Roche, Tibotec and Vertex, and received speaking and teaching fees from AbbVie, Bayer, Bristol–Myers Squibb, Gilead, Janssen, MSD, Novartis, Roche, Sanofi, Tibotec and Vertex. V.B. is on advisory boards for AbbVie and Gilead.
About this article
Cite this article
Colombo, M., Boccaccio, V. HCV therapy and risk of liver cancer recurrence: who to treat?. Nat Rev Gastroenterol Hepatol 15, 392–393 (2018). https://doi.org/10.1038/s41575-018-0018-5